Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART19 for Orphan Indications of Pediatric B-ALL
NCT04276870Phase 2Recruiting
- Start
- Mar 2020
- Primary completion
- Mar 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of tisagenlecleucel in B cell acute lymphoblastic leukemia (B-ALL) (4 arms). Primary endpoint: Event-free survival at 1 year. Started Mar 2020; status: recruiting.
02
Drugs
tisagenlecleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04276870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04276870.